Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q2 FY24 Earnings Presentation
14 slides from Gland Pharma's earnings presentation, Nov 6, 2023
Slide 1: Gland Pharma Limited Financial Results Q2'FY24
Gland Pharma Limited Financial Results Q2’FY24 06th November 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Group Financial Highlights (1/4)
Group Financial Highlights (1/4) Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (INR Mn) (INR Mn / %) 25,821 16,077 19,013 62% 10,078 13,734 8,519 12,087 7,558 10,444 53% 5,249 63% 62% 50% Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24 Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24 EBITDA (3)
Slide 4: Gland Financial Highlights (Ex-Cenexi) (2/4)
Gland Financial Highlights (Ex-Cenexi) (2/4) Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn / %) (INR Mn) 0.03% 19,013 19,019 6,109 5,668 -3% 32% 17% 30% 10,444 3,473 10,146 2,969 8,873 2,636 34% 28% 30% Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24 Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24
Slide 5: Group Financial Highlights (3/4)
Group Financial Highlights (3/4) Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 79,587 83,067 37,707 37,669 22,627 19,500 Mar'23 Sep'23 Mar'23 Sep'23 Networth Total Cash Net Cash Net Working Capital (3) Capital Expenditure (INR Mn) (INR Mn) 24,010 22,904 1,657 825 Mar'23 Sep'2
Slide 6: Group Financial Highlights (4/4)
Group Financial Highlights (4/4) Asset Turnover Ratio (1)(2) ROCE (3) / RONW (4) (%) 2.4 13% 2.2 2.1 11% 13% 10% 11% 10% 0.5 0.5 0.6 Total asset turnover Fixed asset turnover 6M FY23 FY23 6M FY24 6M FY23 FY23 6M FY24 RoCE RoNW Cash Flow from Operations Cash Conversion Cycle (CCC) (5)(6) (INR Mn) (#
Slide 7: P&L Highlights
P&L Highlights Group P&L (INR Mn) Particulars Q2 FY24 Q2 FY23 YoY 6M FY24 6M FY23 YoY Q1 FY24 QoQ Revenue from operations 13,734 10,444 32% 25,821 19,013 36% 12,087 14% Other Income 532 656 -19% 907 1,400 -35% 375 42% Total Income 14,266 11,100 29% 26,728 20,413 31% 12,462 14% Gross Margin(1) 8,519
Slide 8: Q2 FY24 key highlights
Q2 FY24 key highlights Gland (Ex-Cenexi) ❖ Pricing and market share trends have shown encouraging indicators of normalization in our key products, notably in the United States, contributing to our revenue growth. ❖ Business stability is reinstating confidence in base products, and the outlook for fu
Slide 9: US Market
US Market Group Revenue Contribution ▪ Revenue: Launched 14 molecules in the market, including 6M FY24: Rs. 13,375 Mn Q2 FY24: Rs. 7,354 Mn YoY Change: 2% YoY Change: 9% Calcitriol, Fluphenazine, and Desmopressin. Increase in volume for some of the key products, such as Ketorolac Tromethamine, Rocur
Slide 10: Europe, Other Core Markets (Canada, Australia and New Zealand)
Europe, Other Core Markets (Canada, Australia and New Zealand) Europe Other Core Markets (Canada, Australia and New Zealand) Group Revenue Contribution Group Revenue Contribution 6M FY24: Rs. 4,712 Mn Q2 FY24: Rs. 2,488 Mn 6M FY24: Rs. 616 Mn Q2 FY24: Rs. 356 Mn YoY Change: 402% YoY Change: 379% YoY
Slide 11: Rest of the World Markets
Rest of the World Markets Group Revenue Contribution Rest of the World Markets (Ex-Cenexi) ▪ Our Rest of the World markets contributed 17% of our 6M FY24: Rs. 5,596 Mn Q2 FY24: Rs. 2,660 Mn YoY Change: 72% YoY Change: 19% revenue in Q2 FY24, compared to 21% in Q2 FY23. 21% 19% ▪ We expect the RoW de
Slide 12: India (Domestic Market)
India (Domestic Market) Group Revenue Contribution India - Domestic Market (Ex-Cenexi) 6M FY24: Rs. 1,523 Mn Q2 FY24: Rs. 876 Mn ▪ The India market accounts for 9% of our Q2FY24 YoY Change: 23% YoY Change: 21% 6% revenue and has seen growth of 21% as compared to 7% the same quarter last year. Q2 Q2
Slide 13: Long term growth drivers
Long term growth drivers 1 ▪ China remains a key geographic focus, having received and launched one product this year. ▪ Enhanced geographical footprint in Europe through acquisition and integration of Cenexi for CDMO operations and Geographic new B2B partnerships in other markets through portfolio
Slide 14: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder